This is an aggregated industry headline. Read the full story at BioPharma Dive →
Roche scraps two Ionis-partnered Huntington's drugs
The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
By BioPharma Dive
· Jul 9, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Bleeding disorder patient groups put Sobi, Roche and Novo Nordisk on the podium in 2025/2026's corporate reput…
The WeekFierceBiotech ↗
The Advanced Research Projects Agency for Health has awarded a new tranche of funds for companies and institut…
The WeekBriefing
The August 5 meeting will explore how to identify and prioritize FDA-approved drugs for new indications and po…